LifeMD (LFMD) said Tuesday that it plans to offer "broad, affordable, and streamlined" access to Novo Nordisk's (NVO) weight-loss drug Wegovy.
The company said all doses of Wegovy are available in a pen device to eligible LifeMD patients who are uninsured or do not have weight-loss medication coverage through their insurance provider.
Shares of LifeMD surged 22% in early trading Tuesday.
Price: 7.47, Change: +1.37, Percent Change: +22.46
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。